RecruitingNCT07630649
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
PHASE2 · 15 planned enrolment
- Countries listed
- 1
- Registry update
- August 5, 2026
immortal.lifeTrial registrations containing the exact intervention label Ixo-vec.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE2 · 15 planned enrolment
PHASE3 · 311 planned enrolment